Table 1.
Baseline Demographic and Clinical Characteristics of Patients With Advanced HCC
| Characteristic | Patients (N = 187) |
|---|---|
| Age, years | |
| Median | 64 |
| Range | 24-88 |
| Sex, % | |
| Male | 75 |
| Female | 25 |
| Ethnicity, % | |
| White | 63 |
| African American | 12 |
| Asian | 20 |
| Hispanic | 4 |
| Unknown | 1 |
| Cirrhosis, % | |
| Yes | 55 |
| No | 45 |
| Etiology, % | |
| Hepatitis C | 30 |
| Hepatitis B | 33 |
| Alcohol | 30 |
| Other | 14 |
| None | 24 |
| Symptoms, % | |
| Present | 78 |
| Absent | 22 |
| ECOG PS, % | |
| 0-1 | 80 |
| 2-3 | 20 |
| Abdominal pain, % | |
| Yes | 34 |
| No | 66 |
| Weight loss, % | |
| Yes | 33 |
| No | 67 |
| Ascites, % | |
| Yes | 18 |
| No | 82 |
| Encephalopathy, % | |
| Yes | 2 |
| No | 98 |
| Esophageal varices, % | |
| Yes | 21 |
| No | 73 |
| Laboratory values, medians | |
| Total bilirubin, mg/dL | 1.1 |
| Albumin, g/dL | 3.2 |
| PT | 1.06 |
| Platelets, K/μL | 179 |
| Alkaline phosphatase, U/L | 146 |
| AST, U/L | 72 |
| ALT, U/L | 45 |
| AFP, ng/mL | 355 |
| Total bilirubin, mg/dL | 1.1 |
| Albumin, g/dL | 3.2 |
| Liver function by Child-Pugh stage, % | |
| A | 67 |
| B | 29 |
| C | 4 |
| Tumor characteristic, % | |
| No. of liver tumors | |
| 0 | 6 |
| 1-5 | 39 |
| > 5 | 55 |
| Diameter of largest lesion, cm | 6.7 |
| Bilobar disease | |
| Yes | 70 |
| No | 30 |
| Extent | |
| ≤ 50% | 70 |
| > 50% | 30 |
| Vascular invasion | |
| Yes | 36 |
| No | 64 |
| Portal vein thromboses | |
| Yes | 30 |
| No | 70 |
| Organ invasion | |
| Yes | 4 |
| No | 96 |
| T | |
| 0-2 | 36 |
| 3-4 | 64 |
| N | |
| Yes | 37 |
| No | 63 |
| M | |
| Yes | 60 |
| No | 40 |
| Previous treatment, % | |
| No. of previous treatments | |
| 0 | 43 |
| 1 | 32 |
| ≥ 2 | 25 |
| Surgery | 25 |
| Embolization | 34 |
| Ablation | 14 |
| Chemoembolization | 6 |
| Chemotherapy | 4 |
| Transplantation | 1 |
| Treatment offered, % | |
| Clinical trial | 29 |
| Chemotherapy | 33 |
| Best supportive care | 38 |
| Staging system | |
| TNM* | |
| 1-2 | 6 |
| 2 | 32 |
| 3 | 63 |
| Okuda stage | |
| 1 | 49 |
| 2 | 40 |
| 3 | 11 |
| BCLC | 1 |
| A | 1 |
| B | 1 |
| C | 85 |
| D | 13 |
| CLIP score | 9 |
| 0 | 9 |
| 1 | 19 |
| 2 | 31 |
| 3 | 23 |
| 4 | 12 |
| 5 | 6 |
| CUPI | 38 |
| Low | 38 |
| Intermediate | 50 |
| High | 12 |
| JIS score | 0 |
| 0 | 0 |
| 1 | 2 |
| 2 | 8 |
| 3 | 64 |
| 4 | 22 |
| 5 | 3 |
| GETCH | 15 |
| Low | 15 |
| Intermediate | 71 |
| High | 14 |
Abbreviations: HCC, hepatocellular carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; PT, prothrombin time; AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; CUPI, Chinese University Prognostic Index; JIS, Japan Integrated Staging; GETCH, Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.
*
Sixth edition.